Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Zimmer Biomet Holdings Inc (NYSE: ZBH) closed the day trading at $88.34 down -3.40% from the previous closing price of $91.45. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 4.14 million shares were traded. ZBH stock price reached its highest trading level at $93.62 during the session, while it also had its lowest trading level at $87.3.
Ratios:
For a better understanding of ZBH, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.51. For the most recent quarter (mrq), Quick Ratio is recorded 1.39 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.59.
Evercore ISI Upgraded its In-line to Outperform on January 05, 2026, while the target price for the stock was maintained at $210.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 11 ’25 when Yi Sang sold 1,200 shares for $103.58 per share. The transaction valued at 124,302 led to the insider holds 18,584 shares of the business.
Yi Sang bought 1,200 shares of ZBH for $124,302 on Sep 11 ’25. On Sep 08 ’25, another insider, Winkler Lori, who serves as the SVP and CHRO of the company, sold 1,500 shares for $104.15 each. As a result, the insider received 156,225 and left with 6,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBH now has a Market Capitalization of 17507356672 and an Enterprise Value of 24447758336. As of this moment, Zimmer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.86, and their Forward P/E ratio for the next fiscal year is 10.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 3.052 whereas that against EBITDA is 9.259.
Stock Price History:
The Beta on a monthly basis for ZBH is 0.63, which has changed by -0.14139515 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, ZBH has reached a high of $114.44, while it has fallen to a 52-week low of $85.33. The 50-Day Moving Average of the stock is -4.07%, while the 200-Day Moving Average is calculated to be -8.78%.
Shares Statistics:
Over the past 3-months, ZBH traded about 2.04M shares per day on average, while over the past 10 days, ZBH traded about 1607650 shares per day. A total of 198.20M shares are outstanding, with a floating share count of 197.91M. Insiders hold about 0.14% of the company’s shares, while institutions hold 99.78% stake in the company. Shares short for ZBH as of 1767139200 were 10334707 with a Short Ratio of 5.06, compared to 1764288000 on 8496861. Therefore, it implies a Short% of Shares Outstanding of 10334707 and a Short% of Float of 5.9799999999999995.
Dividends & Splits
ZBH’s forward annual dividend rate is 0.96, up from 0.96 a year ago. Against a Trailing Annual Dividend Yield of 0.010497539. The stock’s 5-year Average Dividend Yield is 0.81. The current Payout Ratio is 21.66% for ZBH, which recently paid a dividend on 2025-12-30 with an ex-dividend date of 2025-12-30. Stock splits for the company last occurred on 2022-03-01 when the company split stock in a 103:100 ratio.
Earnings Estimates
The stock of Zimmer Biomet Holdings Inc (ZBH) is currently in the spotlight, with 25.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $1.92, with high estimates of $2.04 and low estimates of $1.78.
Analysts are recommending an EPS of between $8.23 and $8.11 for the fiscal current year, implying an average EPS of $8.17. EPS for the following year is $8.48, with 27.0 analysts recommending between $8.66 and $8.26.
Revenue Estimates
23 analysts predict $2.22B in revenue. The current quarter. It ranges from a high estimate of $2.24B to a low estimate of $2.2B. As of. The current estimate, Zimmer Biomet Holdings Inc’s year-ago sales were $2.02BFor the next quarter, 23 analysts are estimating revenue of $2.06B. There is a high estimate of $2.12B for the next quarter, whereas the lowest estimate is $1.99B.
A total of 26 analysts have provided revenue estimates for ZBH’s current fiscal year. The highest revenue estimate was $8.23B, while the lowest revenue estimate was $8.16B, resulting in an average revenue estimate of $8.21B. In the same quarter a year ago, actual revenue was $7.68BBased on 24 analysts’ estimates, the company’s revenue will be $8.63B in the next fiscal year. The high estimate is $8.75B and the low estimate is $8.34B.
